Seegene Unveils CURECA™ and STAgora™ at ADLM 2025: A New Era in Diagnostics

Seegene Pioneers Diagnostic Automation with Innovative Technologies

During the ADLM 2025 convention held from July 29-31 in Chicago, Seegene Inc., a leader in molecular diagnostics, showcased its cutting-edge technologies: CURECA™, the world's first fully autonomous PCR testing system, and STAgora™, an innovative platform for real-time global data analysis. Dr. Jong-Yoon Chun, the Chairman and CEO of Seegene, highlighted the significant progress in the field of molecular diagnostics toward complete automation, crucial for enhancing healthcare efficiency and addressing infectious diseases.

CURECA™ is designed to automate the entire PCR testing process. This revolutionary system not only handles sample preparation but also ensures continuous data processing and minimizes reliance on specialized staff. Traditional molecular testing systems often require manual intervention, creating inefficiencies and scalability issues. However, CURECA™ eliminates these barriers by employing a comprehensive automation model that operates 24/7, thereby reducing human error and increasing operational throughput.

Dr. Chun emphasized the importance of seamless integration for diagnostics, stating that CURECA™ is at the forefront of transforming molecular testing capabilities. "Our objective is to enable laboratories worldwide to automate complex diagnostic processes efficiently," he said. The CURECA™ system is capable of processing a wide variety of samples, including urine, blood, and sputum, which are traditionally challenging to automate due to their varying characteristics.

STAgora™: Enhancing Data-Driven Decision Making
In addition to CURECA™, Seegene introduced STAgora™, an advanced data analysis platform that provides laboratories with real-time insights from PCR testing. It features over 40 analytical tools designed to track infection dynamics, monitor patients requiring hospitalization, and analyze co-infection patterns. STAgora™ goes beyond mere data storage—it facilitates comprehensive aggregation of insights, allowing hospitals to establish their statistical databases and swiftly identify patterns in infectious data.

The platform's design ensures the privacy of sensitive information while still allowing for efficient communication of insights on a local, national, and global scale. Dr. Chun pointed out that STAgora™ addresses the current limitations of diagnostic data, which often lacks context and broader reference points. "With STAgora™, we aim to revolutionize how diagnostic insights are utilized, helping laboratories to make informed, data-driven decisions quickly," he remarked.

As a part of Seegene's long-term vision of a 'disease-free world,' these technologies are an extension of the company's existing portfolio, which includes proprietary PCR technology and the SGDDS (Seegene Digitalized Development System) that automates molecular test development. Experts attending the ADLM 2025 expressed keen interest in Seegene's advancements, noting that CURECA™ represents one of the most significant innovations presented at the event.

A Promising Future for Molecular Diagnostics
With CURECA™ and STAgora™, Seegene is committed to breaking down long-standing barriers in molecular diagnostics. As the company develops these technologies further, it aims to maximize the use of diagnostic data and facilitate automation in laboratories worldwide. Dr. Chun concluded, stating, "Just as smartphones and electric vehicles transformed their sectors, we believe CURECA™ and STAgora™ will redefine the landscape of diagnostic testing, paving the way for true automation and ultimately contributing to a healthier world."

It’s important to note that both CURECA™ and STAgora™ are still under development and are not yet commercially available or approved for clinical use. Seegene plans to continue enhancing these systems, aligning with its mission to lead the future of diagnostics.